BREAKING:

This financial report captures a pivotal moment for the Group, marked by major changes in business scope and strategic divestments. The performance reflects a significant non-operating boost from the sale of a key equity interest. While facing external pressures, particularly within the upstream supply chain of the Traditional Chinese Medicine (TCM) industry, the Group is moving forward by deepening its brand-led strategy and investing heavily in research and development.

• Discover the exceptional transaction that delivered a substantial non-operating gain to the Group’s bottom line during the period

• Learn how changes in the consolidation boundary, specifically the exclusion of data from a former subsidiary, redefine the reported figures for revenue and various costs

• Examine the strategic shift within the TCM industry toward "quality and value first" and how the Group is adapting to intense supply-chain pressures

WATCH THE EXPLAINER VIDEO BELOW:

LISTEN TO THE PODCAST BELOW:

There will be an EGM on

Event dates:

For more information, click here: TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED 2023 EGM

There will be an AGM on

Event dates:

For more information, click here: TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED 2023 AGM